Comparative Pharmacology
Head-to-head clinical analysis: ACCRUFER versus FERUMOXYTOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACCRUFER versus FERUMOXYTOL.
ACCRUFER vs FERUMOXYTOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACCRUFER (ferric maltol) is an oral iron replacement therapy. Ferric iron is complexed with maltol, which enhances absorption. Once absorbed, iron is utilized for hemoglobin synthesis and erythropoiesis.
Ferumoxytol is an ultrasmall superparamagnetic iron oxide nanoparticle that provides a source of iron for erythropoiesis. It is phagocytosed by macrophages of the reticuloendothelial system, and iron is released intracellularly to bind to transferrin and ferritin, replenishing iron stores.
170 mg (1 tablet) orally twice daily (340 mg total daily dose) for adults with iron deficiency anemia, taken on an empty stomach at least 1 hour before or 2 hours after meals.
510 mg intravenously once, followed by 510 mg intravenously 3 to 8 days later for a total cumulative dose of 1020 mg. Administer as a slow IV injection at 1 mL/min (30 mg/min) undiluted or diluted in 50-200 mL normal saline.
None Documented
None Documented
20 hours (prolonged in hepatic impairment)
Terminal elimination half-life is approximately 14-21 hours in healthy adults; prolonged in patients with iron deficiency anemia (up to 30 hours) due to increased iron utilization.
Renal 65% (as unchanged drug), fecal 35%
Ferumoxytol is eliminated primarily through the reticuloendothelial system, with the iron moiety incorporated into hemoglobin or stored as ferritin/hemosiderin. Minimal renal or biliary excretion of intact drug; <1% excreted unchanged in urine.
Category C
Category C
Iron Replacement
Iron Replacement